The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
Abstract
Cancer still represents a "nightmare" worldwide, causing annually millions of victims. Several antiproliferative molecules are currently used as drugs market and offer a pharmaceutical opportunity for attenuating and treating tumor manifestations. In this context, natural sources have a relevant role, since they provide the 60% of currently-used anticancer agents. Among the numerous natural products, acting via different mechanisms of action, microtubule-targeting agents (MTAs) have a high therapeutic potential, since they disrupt the abnormal cancer cell growth, interfering with the continuous mitotic division. Vinca alkaloids (VAs) are the earliest developed MTAs and approved for clinical use (Vincristine, Vinblastine, Vinorelbine, Vindesine, and Vinflunine) as agents in the treatment of hematological and lymphatic neoplasms. Here, we review the state-of-art of VAs, discussing their mechanism of action and pharmacokinetic properties and highlighting their therapeutic relevance and toxicological profile. Additionally, we briefly disclosed the technological approaches faced so far to ameliorate the pharmacological properties, as well as to avoid the drug resistance. Lastly, we introduced the recent advances in the discovery of new derivatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
MICROTUBULE POLYMERIZATION DYNAMICS
Desai, A., & Mitchison, T. J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.83 · Cited by 2,563
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
(2016) · Wiley eBooks · doi:10.1002/9781119000822 · Cited by 1,148
Ueda, K., Cardarelli, C., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3004 · Cited by 1,063
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Structural basis for the regulation of tubulin by vinblastine
Gigant, B., Wang, C., Ravelli, R. B. G., Roussi, F., Steinmetz, M. O., Curmi, P. A., Sobel, A., & Knossow, M. (2005) · Nature · doi:10.1038/nature03566 · Cited by 734
Natural products as leads to anticancer drugs
Gordaliza, M. (2007) · Clinical and Translational Oncology · doi:10.1007/s12094-007-0138-9 · Cited by 701
Natural products in anticancer therapy
da Rocha, A. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00063-7 · Cited by 604
THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.
JOHNSON, I. S., Jg, A., Gorman, M., & Jp, B. (1963) · PubMed · Cited by 564
From traditional Chinese medicine to rational cancer therapy
Efferth, T., Li, P. C. H., Konkimalla, V. S. B., & Kaina, B. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.001 · Cited by 528
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
Rowinsky, E. K., & Donehower, R. C. (1991) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(91)90086-2 · Cited by 321
Review: Tubulin Function, Action of Antitubulin Drugs, and New Drug Development
Pellegrini, F., & Budman, D. R. (2005) · Cancer Investigation · doi:10.1081/cnv-200055970 · Cited by 313
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Bates, D., & Eastman, A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13126 · Cited by 298
The long story of camptothecin: From traditional medicine to drugs
Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.085 · Cited by 296
Self-citationAnticancer Agents from Natural Products
(2011) · CRC Press eBooks · doi:10.1201/b11185 · Cited by 256
Gidding, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(98)00023-7 · Cited by 251
Microtubule dynamics as a target in oncology
Risinger, A. L., Giles, F. J., & Mooberry, S. L. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.001 · Cited by 248
Naumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., Gabrail, N. Y., DePasquale, S. E., Nowara, E., Gilbert, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7685 · Cited by 238
Kavallaris, M., Tait, A., Walsh, B. J., He, L., Horwitz, S. B., Norris, M. D., & Haber, M. (2001) · PubMed · Cited by 221
Microtubule Dynamics and Kinetochore Function in Mitosis
Mitchison, T. J. (1988) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.04.110188.002523 · Cited by 208
Sears, J. E., & Boger, D. L. (2015) · Accounts of Chemical Research · doi:10.1021/ar500400w · Cited by 201
O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., Aulitzky, W., Ben-Yehuda, D., Stock, W., Coutre, S., Douer, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2309 · Cited by 196
PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs
Khan, T., & Gurav, P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.01002 · Cited by 165
Pharmacokinetic Interactions Between Antiepileptic Drugs
Riva, R., Albani, F., Contin, M., & Baruzzi, A. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631060-00005 · Cited by 157
Gregory, R. K., & Smith, I. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1203 · Cited by 141
Ling, G., Zhang, P., Zhang, W., Sun, J., Meng, X., Qin, Y., Deng, Y., & He, Z. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.010 · Cited by 136
New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer
Zhang, Y., Yang, S.-H., & Guo, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.041 · Cited by 130
Vlahov, I. R., Santhapuram, H. K. R., Kleindl, P. J., Howard, S. J., Stanford, K., & Leamon, C. P. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.07.030 · Cited by 128
Vinflunine: A New Microtubule Inhibitor Agent
Bennouna, J., Delord, J., Campone, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2219 · Cited by 128
The evolution of drug discovery: from traditional medicines to modern drugs
(2011) · Choice Reviews Online · doi:10.5860/choice.49-0899 · Cited by 127
Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Lucas, D. M., Still, P. C., Pérez, L. B., Grever, M. R., & Kinghorn, A. D. (2010) · Current Drug Targets · doi:10.2174/138945010791320809 · Cited by 121
Dandamudi, S., & Campbell, R. B. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.07.024 · Cited by 118
Microtubule-Binding Natural Products for Cancer Therapy
Yue, Q., Liu, X., & Guo, D. (2010) · Planta Medica · doi:10.1055/s-0030-1250073 · Cited by 114
A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
Yurkovetskiy, A., Yin, M., Bodyak, N. D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0129 · Cited by 106
Tubulin inhibitors: a patent review
Liu, Y.-M., Chen, H., Lee, H., & Liou, J. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.859247 · Cited by 104
Modifications on the Basic Skeletons of Vinblastine and Vincristine
Keglevich, P., Hazai, L., Kalaus, G., et al. (2012) · Molecules · doi:10.3390/molecules17055893 · Cited by 101
Chen, J., Li, S., & Shen, Q. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.07.002 · Cited by 98
Kruczynski, A., Poli, M., Dossi, R., Chazottes, E., Berrichon, G., Ricome, C., Giavazzi, R., Hill, B. T., & Taraboletti, G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.019 · Cited by 93
Noble, C. O., Guo, Z., Hayes, M. E., Marks, J. D., Park, J. W., Benz, C. C., Kirpotin, D. B., & Drummond, D. C. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0923-3 · Cited by 88
Wang, Y., Dou, L., He, H., Zhang, Y., & Shen, Q. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400547u · Cited by 78
Fahy, J. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397483 · Cited by 73
Second generation liposomal cancer therapeutics: Transition from laboratory to clinic
Sen, K., & Mandal, M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.03.006 · Cited by 72
Total Synthesis and Evaluation of a Key Series of C5-Substituted Vinblastine Derivatives
Va, P., Campbell, E., Robertson, W. M., & Boger, D. L. (2010) · Journal of the American Chemical Society · doi:10.1021/ja1027748 · Cited by 66
Poruchynsky, M. S., Giannakakou, P., Ward, Y., Bulinski, J. C., Telford, W. G., Robey, R. W., & Fojo, T. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00804-8 · Cited by 59
Barker, T. J., Duncan, K. K., Otrubova, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400281w · Cited by 55
Development and characteristics of temperature-sensitive liposomes for vinorelbine bitartrate
Zhang, H., Wang, Z., Gong, W., Li, Z., Mei, X., & Lv, W.-L. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.013 · Cited by 50
Stabilization of Vinca Alkaloids Encapsulated in Poly(lactide-co-glycolide) Microspheres
Marinina, J., Shenderova, A., Mallery, S. R., & Schwendeman, S. P. (2000) · Pharmaceutical Research · doi:10.1023/a:1007522013835 · Cited by 47
Lobert, S., Fahy, J., Hill, B. T., Duflos, A., Etiévant, C., & Correia, J. J. (2000) · Biochemistry · doi:10.1021/bi001038r · Cited by 47
Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues
Haque, A., Rahman, M. A., Faizi, M. S. H., et al. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170502123639 · Cited by 46
Patra, S., & Sundaram, M. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-331 · Cited by 41
Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung
Edelman, M. J., Harb, W. A., Pal, S. E., Boccia, R. V., Kraut, M., Bonomi, P., Conley, B. A., Rogers, J., Messmann, R. A., & Garon, E. B. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318267d051 · Cited by 36
Kaplan, L. D., Deitcher, S. R., Silverman, J. A., & Morgan, G. J. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.09.009 · Cited by 36
Vinflunine: clinical perspectives of an emerging anticancer agent
Yip, A. Y.-S., Ong, E. Y.-Y., & Chow, L. W. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.4.583 · Cited by 31
Joel, S. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90015-2 · Cited by 30
Pathak, P., Hess, R., & Weiss, M. A. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620713519016 · Cited by 29
Yang, Y., Guo, Y., Tan, X., He, H., Zhang, Y. X., Yin, T., Xu, H., & Tang, X. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.09.045 · Cited by 15
Saba, N., & Seal, A. (2018) · Journal of Molecular Modeling · doi:10.1007/s00894-018-3611-1 · Cited by 11
Cyclopropanation of Some Alkaloids
Keglevich, P., Hazai, L., Kalaus, G., & Szántay, C. (2015) · Periodica Polytechnica Chemical Engineering · doi:10.3311/ppch.7257 · Cited by 9
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01614 · Cited by 1,086
Dhyani, P., Quispe, C., Sharma, E., Bahukhandi, A., Sati, P., Attri, D. C., Szopa, A., Sharifi-Rad, J., Docea, A. O., Mardare, I., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02624-9 · Cited by 483
Regulation of microtubule dynamics, mechanics and function through the growing tip
Gudimchuk, N. B., & McIntosh, J. R. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00399-x · Cited by 369
Status and Challenges of Plant-Anticancer Compounds in Cancer Treatment
Garcia-Oliveira, P., Otero, P., Pereira, A. G., Chamorro, F., Carpena, M., Echave, J., Fraga-Corral, M., Simal-Gandara, J., & Prieto, M. A. (2021) · Pharmaceuticals · doi:10.3390/ph14020157 · Cited by 303
Metadata
- Authors
- Martino, E., Casamassima, G., Castiglione, S., Cellupica, E., Pantalone, S., Papagni, F., Rui, M., Siciliano, A. M., & Collina, S.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 28
- Issue
- 17
- Pages
- 2816-2826
- ISSN
- 0960-894X (ISSN-L)
- OpenAlex
- W2810294944
- Cited by
- 337
- References
- 65
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.